Medicare AdvantageCoverageHigh impact
MA08.045q, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection
Independence Blue Cross·Rheumatology, Oncology, Gastroenterology +1 more·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 23, 2026
Summary
MA08.045q is a new Medicare Advantage policy effective 07/01/2026 governing coverage and billing for Tocilizumab and related biosimilars administered via intravenous infusion and subcutaneous injection. The billing team must review the full policy text to identify specific prior authorization requirements, covered indications, dosing parameters, and applicable HCPCS codes for these biologic medications.
Action Required
By 06/30/2026: Billing team must obtain and review the complete MA08.045q policy document from the provided URL to identify: (1) specific HCPCS codes for Tocilizumab and biosimilars (likely J-codes), (2) prior authorization requirements and submission procedures, (3) covered medical conditions and limitations, (4) documentation requirements. Update billing system rules, prior auth workflows, and provider encounter templates accordingly. Communicate requirements to providers and infusion center staff. Beginning 07/01/2026, all Tocilizumab and biosimilar claims must comply with this policy or face denial. Note: Policy content details are not visible in the source provided; access the full policy document immediately to ensure timely implementation.